Venture Capital Deals and Investments
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Venture Capital Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
Electra Therapeutics Raises $183M Series C to Fund Pivotal Rare Disease Trial
Series CVenture Capital

Electra Therapeutics Raises $183M Series C to Fund Pivotal Rare Disease Trial

•October 27, 2025
•Oct 27, 2025
0

Participants

Electra Therapeutics

Electra Therapeutics

company

Sanofi

Sanofi

investor

RA Capital

RA Capital

investor

Blue Owl Capital

Blue Owl Capital

investor

EQT

EQT

investor

Mubadala Capital

Mubadala Capital

investor

Nextech

Nextech

investor

OrbiMed

OrbiMed

investor

Why It Matters

The capital infusion enables Electra to advance its rare‑disease therapy toward regulatory approval, positioning the company for market entry and attracting further strategic partnerships in the biotech sector.

Deal Summary

Electra Therapeutics announced a $183 million Series C financing to support a newly launched pivotal trial for its rare disease candidate. The round was co-led by Nextech and EQT Life Sciences with participation from Sanofi, Mubadala Capital, OrbiMed, Blue Owl Capital and RA Capital Management.

0

Comments

Want to join the conversation?

Loading comments...